TABLE 2.
Characterization of ART-treated HIV-2+ cohortsa
| Parameter | ART HIV-2 aviremic | ART HIV-2 viremic | ART HIV-2 (all) |
|---|---|---|---|
| No. (male/female) | 11 (5/6) | 5 (3/2) | 16 (8/8) |
| Median age (range) (yr) | 54 (34-62) | 53 (31-62) | 54 (31-62) |
| Current ART regimen (no. of patients) | |||
| 2 NRTI | 3 | 3 | |
| 2 NRTI + 1 PI | 6 | 4 | 10 |
| 3 NRTI | 2 | 1 | 3 |
| Length of follow-up (range) (mo) | |||
| Under ART | 28 (1-109) | 66 (6-120) | 58 (1-120) |
| After HIV diagnosis | 65 (8-242) | 177 (29-220) | 97 (8-242) |
| CD4 T cells/μl (range) | 340 (70-554) | 163 (84-719) | 302 (70-719) |
| % CD4 T cells (range) | 22 (5-36) | 10 (4-23) | 20 (4-36) |
| CD8 T cells/μl (range) | 825 (244-1,419) | 912 (447-1,532) | 887 (244-1,532) |
| % CD8 T cells (range) | 50 (26-64) | 53 (49-65) | 51 (26-65) |
| Viremia (RNA copies/ml) (range) | 200 | 4172 (499-34,314) | 200 (200-34,314) |
| Proviral DNA (copies/106 PBMC) (range)b | 108 (5-346) | 5 (5-726) | 57 (5-726.0) |
a
Values are medians, with limits in brackets. Test cutoff value was used to calculate the median if levels were below cutoff. NRTI, nucleoside RT inhibitor; PI, protease inhibitor.
b
Proviral DNA was below 5 copies/106 PBMC (cutoff) in 5 out of 11 aviremic and in 3 out of 5 viremic treated HIV-2 patients.